The immunotherapies used to treat melanoma now include well-established drugs such as Keytruda (pembrolizumab) and Opdivo (nivolumab) and newer ones such as Amtagvi (lifileucel), which uses T cells ...
XmAb819 demonstrated a manageable safety profile with primarily grade 1 or 2 cytokine release syndrome and no neurotoxicity in ccRCC patients. The trial involved 69 patients, with a 25% objective ...
A groundbreaking study introduces new noninvasive screening tools that have the potential to greatly enhance patient comfort ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback